Taking a Switch to Cancer Cells
Controlling Means of Production Could Improve Protein Therapies
By Anette Breindl
Monday, October 3, 2011
A frequent challenge for drug developers is how to target drugs especially cancer drug, which aim to kill their target cells to the right cell population. But researchers at Johns Hopkins University have turned this problem on its ear: Instead of delivering drugs specifically to cancer cells, they have developed a way to make cancer cells activate prodrugs through use of molecular switches.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.